Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]

7649 reported adverse events

Drugs of this class: BENRALIZUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] class:

# Side effect Count
0 ASTHMA 1404
1 DYSPNOEA 867
2 DRUG INEFFECTIVE 600
3 HEADACHE 528
4 COUGH 472
5 DEATH 451
6 WHEEZING 416
7 PYREXIA 340
8 RASH 309
9 MALAISE 304
See all common reactions for Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]

Drugs of the Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EOSINOPHILIC OTITIS MEDIA 6 0.4615
1 FRACTIONAL EXHALED NITRIC OXIDE ABNORMAL 2 0.3333
2 CHRONIC EOSINOPHILIC RHINOSINUSITIS 4 0.2500
3 FRACTIONAL EXHALED NITRIC OXIDE INCREASED 6 0.0968
4 CHRONIC RHINOSINUSITIS WITH NASAL POLYPS 2 0.0714
5 EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS 58 0.0638
6 EOSINOPHIL COUNT ABNORMAL 31 0.0588
7 EOSINOPENIA 4 0.0548
8 FORCED EXPIRATORY VOLUME ABNORMAL 5 0.0439
9 ENTEROBIASIS 3 0.0380
See all enriched reactions for Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]